Queen Mary University of London

EndoCompass project: Research roadmap for pituitary and neuroendocrine tumor endocrinology (2025) Castano JP, Dattani MT, Grozinsky-Glasberg S, Karavitaki N, Pavel ME, Andoniadou C, Alexandraki K, et al. Journal article, Review article A core outcome set for pituitary surgery research: an international delphi consensus study (2025) Valetopoulou A, Newall N, Khan DZ, Borg A, Bouloux PM, Bremner F, Buchfelder M, et al. Journal article Identifying research priorities for pituitary adenoma surgery: an international Delphi consensus statement (2025) Newall N, Valetopoulou A, Khan DZ, Borg A, Bouloux PM, Bremner F, Buchfelder M, et al. Journal article Electrospun porous phosphate-based glass fibres containing gallium and clove oil: Cytotoxicity and antioxidant properties (2025) Moghaddam Z, Nery ET, Ünalan I, Hoxha A, Felipe-Sotelo M, Zhao H, Pinna A, et al. Journal article Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial (2025) Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, et al. Journal article Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial (2025) Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, et al. Journal article A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study (2024) Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, et al. Journal article A bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR (2024) Peri L, Matzov D, Huxley DR, Rainish A, Fierro F, Sapir L, Pfeiffer T, et al. Journal article Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kümmel S, Denkert C, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article